Assertio holdings, inc. announces favorable vote on proposed acquisition of spectrum pharmaceuticals

Stockholders from both assertio and spectrum have overwhelmingly voted in support of the transaction transaction expected to be significantly accretive to assertio in 2024 lake forest, ill. and boston, july 27, 2023 (globe newswire) -- assertio holdings, inc. (“assertio” or the “company”) (nasdaq: asrt), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of spectrum pharmaceuticals, inc. (“spectrum”) (nasdaq: sppi), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which assertio will acquire spectrum in an all-stock and contingent value rights (cvr) transaction.
ASRT Ratings Summary
ASRT Quant Ranking